Trial Profile
Cytotoxic activity as a prognostic tool for Racotumomab Immunotherapy in patients with Advanced Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Feb 2020
Price :
$35
*
At a glance
- Drugs Racotumomab (Primary)
- Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 07 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer